Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 108; no. 8; pp. 2755 - 2763
Main Authors Chng, Wee J., Schop, Roelandt F., Price-Troska, Tammy, Ghobrial, Irene, Kay, Neil, Jelinek, Diane F., Gertz, Morie A., Dispenzieri, Angela, Lacy, Martha, Kyle, Robert A., Greipp, Philip R., Tschumper, Renee C., Fonseca, Rafael, Bergsagel, Peter Leif
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.10.2006
2006 by The American Society of Hematology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Supported in part by grants R01 CA83724-01, Specialized Program of Research Excellence (SPORE) P50 CA100707-01, and P01 CA62242 from the National Cancer Institute; the International Waldenström's Macroglobulinemia Foundation; and the Fund to Cure Myeloma. N.K. is supported in part by National Institutes of Health/National Cancer Institute grant CA 95241 and philanthropic support from the Donaldson Charitable Trust, Mr E. Spencer, and the Donner families. W.J.C. is funded by an International Fellowship from the Agency for Science, Technology and Research (A*STAR), Singapore.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.
An Inside Blood analysis of this article appears at the front of this issue.
Reprints: P. Leif Bergsagel, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259; e-mail: bergsagel.leif@mayo.edu; or Rafael Fonseca, 13208 E Shea Blvd, St 300, Scottsdale, AZ, 85259; e-mail: fonseca.rafael@mayo.edu.
Prepublished online as Blood First Edition Paper, June 27, 2006; DOI 10.1182/blood-2006-02-005488.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2006-02-005488